A61K 9/141
Intimate drug-carrier mixtures characterised by the carrier
Official title: {Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers ((co) spray-dried products A61K9/16, (co) lyophilised products A61K9/19; the carrier being chemically bound to the active ingredient A61K47/50)}
A61K9/141 (Intimate drug-carrier mixtures characterised by the carrier) appears on 3,219 US grants and 5,735 published applications in this corpus.
Search patents in A61K- Granted patents
- 3,219
- Published applications
- 5,735
- Assignees
- 2,350
- Inventors
- 10,232
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 10 | 0 |
| 1977 | 7 | 0 |
| 1978 | 4 | 0 |
| 1979 | 1 | 0 |
| 1980 | 2 | 0 |
| 1981 | 2 | 0 |
| 1982 | 9 | 0 |
| 1983 | 5 | 0 |
| 1984 | 2 | 0 |
| 1985 | 5 | 0 |
| 1986 | 10 | 0 |
| 1987 | 22 | 0 |
| 1988 | 17 | 0 |
| 1989 | 19 | 0 |
| 1990 | 12 | 0 |
| 1991 | 15 | 0 |
| 1992 | 11 | 0 |
| 1993 | 24 | 0 |
| 1994 | 16 | 0 |
| 1995 | 17 | 0 |
| 1996 | 28 | 0 |
| 1997 | 27 | 0 |
| 1998 | 30 | 0 |
| 1999 | 46 | 0 |
| 2000 | 30 | 0 |
| 2001 | 62 | 29 |
| 2002 | 51 | 83 |
| 2003 | 60 | 150 |
| 2004 | 40 | 142 |
| 2005 | 37 | 145 |
| 2006 | 41 | 151 |
| 2007 | 33 | 145 |
| 2008 | 23 | 167 |
| 2009 | 27 | 142 |
| 2010 | 55 | 175 |
| 2011 | 50 | 161 |
| 2012 | 90 | 208 |
| 2013 | 120 | 235 |
| 2014 | 146 | 291 |
| 2015 | 172 | 298 |
| 2016 | 179 | 324 |
| 2017 | 193 | 311 |
| 2018 | 172 | 294 |
| 2019 | 188 | 300 |
| 2020 | 176 | 312 |
| 2021 | 155 | 312 |
| 2022 | 182 | 320 |
| 2023 | 165 | 311 |
| 2024 | 153 | 304 |
| 2025 | 176 | 268 |
| 2026 | 102 | 157 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Nanostructure or microstructure and method for producing same6 Oct 2026US 12,751,923 B2The University of Tokyo
- Implants for release of lipophilic or amphiphilic pharmaceutical substances29 Sep 2026US 12,746,275 B2ReacX Pharmaceuticals, Inc.
- Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto15 Sep 2026US 12,734,145 B2Children's Healthcare of Atlanta, Inc.
- Product8 Sep 2026US 12,728,123 B2Sesh Products Inc.
- Stable lyophilized composition of pemetrexed dipotassium1 Sep 2026US 12,721,811 B1AVYXA Pharma
- Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse8 Oct 2026US 2026/0308532 A1Fred Hutchinson Cancer Center
- Amorphous cabozantinib particles and uses thereof1 Oct 2026US 2026/0294889 A1Flex Pharma, LLC
- Compositions, devices, and methods for intranasal delivery of dry powder epinephrine1 Oct 2026US 2026/0295182 A1Belhaven BioPharma Inc.
- Glycopyrrolate salts24 Sep 2026US 2026/0284007 A1Journey Medical Corporation
- Compositions, devices, and methods for intranasal delivery of dry powder epinephrine24 Sep 2026US 2026/0284335 A1Belhaven BioPharma Inc.
Most cited
By later US patents
- Surface modified drug nanoparticles993US 5,145,684 ASterling Drug Inc. · 1992
- Surface modified anticancer nanoparticles469US 5,399,363 AEastman Kodak Company · 1995
- Lipsopheres for controlled delivery of substances424US 5,188,837 ANova Pharmaceutical Corporation · 1993
- Extruded orally administrable opioid formulations380US 5,958,452 AEuro-Celtique S. A. · 1999
- Extruded multi-particulates364US 5,965,161 AEuro-Celtique S. A. · 1999